Consistently, oral delivery of FAK antagonist (PND-1186) or Src antagonist (saracatinib) into IAV-infected mice from day 7 to day 11 after infection resulted in reduced KRT5+ lung areas compared with control mice receiving PBS (Figure 4, E–G). Here, PTK2 is linked to infection.